183 related articles for article (PubMed ID: 21327725)
1. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Tselepis AD; Elisaf MS
Lipids; 2011 Jun; 46(6):521-8. PubMed ID: 21327725
[TBL] [Abstract][Full Text] [Related]
2. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
[TBL] [Abstract][Full Text] [Related]
4. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Agouridis AP; Kostapanos MS; Tsimihodimos V; Kostara C; Mikhailidis DP; Bairaktari ET; Tselepis AD; Elisaf MS
Int J Clin Pract; 2012 Sep; 66(9):843-53. PubMed ID: 22897461
[TBL] [Abstract][Full Text] [Related]
6. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
Pepine CJ; Jacobson TA; Carlson DM; Kelly MT; Setze CM; Gold A; Stolzenbach JC; Williams LA
Clin Cardiol; 2010 Oct; 33(10):609-619. PubMed ID: 20960535
[TBL] [Abstract][Full Text] [Related]
7. Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions.
Kei A; Liberopoulos E; Tellis C; Elisaf M; Tselepis A
Lipids; 2013 Oct; 48(10):957-65. PubMed ID: 23949918
[TBL] [Abstract][Full Text] [Related]
8. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
10. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
[TBL] [Abstract][Full Text] [Related]
11. [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
Polenova NV; Vaulin NA; Masenko VP; Iavelov IS; Gratsianskiĭ NA
Kardiologiia; 2009; 49(2):9-14. PubMed ID: 19254210
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
[TBL] [Abstract][Full Text] [Related]
13. Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
Lee SH; Cho KI; Kim JY; Ahn YK; Rha SW; Kim YJ; Choi YS; Choi SW; Jeon DW; Min PK; Choi DJ; Baek SH; Kim KS; Byun YS; Jang Y
Atherosclerosis; 2012 Mar; 221(1):169-75. PubMed ID: 22269152
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Jones PH; Davidson MH; Kashyap ML; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Atherosclerosis; 2009 May; 204(1):208-15. PubMed ID: 18996523
[TBL] [Abstract][Full Text] [Related]
15. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Rosenson RS; Carlson DM; Kelly MT; Setze CM; Hirshberg B; Stolzenbach JC; Williams LA
Cardiovasc Drugs Ther; 2011 Feb; 25(1):47-57. PubMed ID: 21174145
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Roth EM; Rosenson RS; Carlson DM; Fukumoto SM; Setze CM; Blasetto JW; Khurmi NS; Stolzenbach JC; Williams LA
Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):421-8. PubMed ID: 20953684
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
19. Are HIV positive patients resistant to statin therapy?
Johns KW; Bennett MT; Bondy GP
Lipids Health Dis; 2007 Oct; 6():27. PubMed ID: 17958912
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Jones PH; Bays HE; Davidson MH; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Clin Drug Investig; 2008; 28(10):625-34. PubMed ID: 18783301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
